20/20 Biolabs, Inc. (AIDX) stock: key figures, P/E, revenue and dividend
Industrials · United States · ISIN US90138K1016
20/20 Biolabs, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.05 m USD |
| Gross profit | 604,541.00 USD |
| Operating income | -3.33 m USD |
| EBIT | -3.60 m USD |
| Net income | -3.74 m USD |
| Diluted EPS – continuing operations | -0.76 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
More stocks
- PSQ Holdings, Inc. (PSQH)
- BioNexus Gene Lab Corp (BGLC)
- Iveda Solutions, Inc. (IVDA)
- ADAMANT DRI PROCESSING & MINERALS GROUP (ADMG)
- RELIABILITY INC (RLBY)
- Co-Diagnostics, Inc. (CODX)
- BioAtla, Inc. (BCAB)
- Cannabis Bioscience International Holdings, Inc. (CBIH)
- LQR House Inc. (YHC)
- TurnOnGreen, Inc. (TOGI)
- BioXcel Therapeutics, Inc. (BTAI)
- Totaligent, Inc. (TGNT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.